Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2019 | Polycystic Ovary Syndrome | Research

Comparison of the umbilical cord Blood’s anti-Mullerian hormone level in the newborns of mothers with polycystic ovary syndrome (PCOS) and healthy mothers

Authors: Faezeh Tadaion Far, Shahideh Jahanian Sadatmahalleh, Saeideh Ziaei, Anoshirvan Kazemnejad

Published in: Journal of Ovarian Research | Issue 1/2019

Abstract

Background

Polycystic ovary syndrome (PCOS) is one of the most common endocrine diseases. At present, the cause of the disease is not fully understood, but many studies have shown that PCOS is associated with genetic and environmental factors. The present study aimed to assess the umbilical cord blood’s Anti-mullerian hormone (AMH) level in the newborns of mothers suffering from PCOS comparing to healthy mothers.

Methods

This prospective cohort study was conducted on 120 pregnant women with PCOS, who were selected through Rotterdam criteria, and 60 healthy pregnant women as the control group. The subjects in each group were divided into obese and non-obese mothers according to their body mass index (BMI) before pregnancy. The cord blood samples were collected from the offsprings on the time of childbirth. Finally, the circulating concentrations of AMH in both sexes of the newborns were determined by specific assays.

Results

The research results showed that the blood level of AMH was higher in the neonates of obese mothers with PCOS comparing to the controls (P < 0.001). Mean AMH level was higher in male neonates born from non-obese PCOS mothers than in the controls (P < 0.001); however, there was not a significant difference in the level of AMH in female neonates between these two groups (P = 0.264). Also the level of the above biomarker was higher in both sexes of the neonates belonging to obese PCOS mothers compared with the neonates born from non-obese PCOS mothers (P < 0.001).

Conclusion(s)

It can be said that the cord blood AMH level of neonates from obese women with PCOS is higher than that in the newborns of non-obese PCOS mothers. Further longitudinal studies are needed to confirm the clinical findings of the present research.

Pigny P, Merlen E, Robert Y, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88:5957–62.PubMedCrossRef

Webber L, Stubbs S, Stark J, et al. Formation and early development of follicles in the polycystic ovary. Lancet. 2003;362:1017–21.PubMedCrossRef

Josso N, di Clemente N. TGF-β family members and gonadal development. Trends Endocrinol Metab. 1999;10:216–22.PubMedCrossRef

Lee MM, Donahoe PK. Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocr Rev. 1993;14:152–64.PubMed

Josso N, Cate RL, Picard J-Y, et al. Anti-Müllerian hormone: the Jost factor. Recent Prog Horm Res; 1993. p. 1–59.

Josso N, Lamarre I, Picard J-Y, et al. Anti-Müllerian hormone in early human development. Early Hum Dev. 1993;33:91–9.PubMedCrossRef

Rajpert-De Meyts E, Jørgensen N, Græm N, et al. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab. 1999;84:3836–44.PubMed

Cook CL, Siow Y, Taylor S, Fallat ME. Serum müllerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril. 2000;73:859–61.PubMedCrossRef

Weenen C, Laven JS, von Bergh AR, et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77–83.PubMedCrossRef

10.

Laven JS, Mulders AG, Visser JA, et al. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004;89:318–23.PubMedCrossRef

11.

Piltonen T, Morin-Papunen L, Koivunen R, et al. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005;20:1820–6.PubMedCrossRef

12.

Caruso-Nicoletti M, editor Sindrome dell’ovaio policistico: novità nella diagnosi e nel trattamento. XII Congresso Nazionale Società Italiana di Medicina dell’Adolescenza; 2003.

13.

Cooper HE, Spellacy W, Prem K, Cohen W. Hereditary factors in the stein-Leventhal syndrome. Am J Obstet Gynecol. 1968;100:371–87.PubMedCrossRef

14.

HAGUE WM, ADAMS J, REEDERS ST, PETO TE, JACOBS HS. Familial polycystic ovaries: a genetic disease? Clin Endocrinol. 1988;29:593–605.CrossRef

15.

Wallach EE, Goldzieher JW. Polycystic ovarian disease. Fertil Steril. 1981;35:371–94.CrossRef

16.

Lunde O, Magnus P, Sandvik L, Høglo S. Familial clustering in the polycystic ovarian syndrome. Gynecol Obstet Investig. 1989;28:23–30.CrossRef

17.

Crisosto N, Echiburú B, Maliqueo M, et al. Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters. Fertil Steril. 2012;97:218–24.PubMedCrossRef

18.

Artini PG, Di Berardino O, Simi G, et al. Best methods for identification and treatment of PCOS. Minerva Ginecol. 2010;62:33.PubMed

19.

Sir-Petermann T, Codner E, Maliqueo M, et al. Increased anti-Mullerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:3105–9.PubMedCrossRef

20.

Ns C, Codner E, Maliqueo M, et al. Anti-Mullerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:2739–43.CrossRef

21.

Recabarren SE, Sir-Petermann T, Rios R, et al. Pituitary and testicular function in sons of women with polycystic ovary syndrome from infancy to adulthood. J Clin Endocrinol Metab. 2008;93:3318–24.PubMedCrossRef

22.

Sir-Petermann T, ALd G, Codner E, et al. Relationship between anti-Müllerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome. Reprod Sci. 2012;19:383–90.PubMedCrossRef

23.

Franks S, Gharani N, Waterworth D, et al. The genetic basis of polycystic ovary syndrome. Human reproduction (Oxford, England). 1997;12:2641–8.CrossRef

24.

Urbanek M, Legro RS, Driscoll DA, et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci. 1999;96:8573–8.PubMedCrossRefPubMedCentral

25.

Barker DJP. Mothers, babies and disease in later life: BMJ publishing group; 1994.

26.

Holemans K, Aerts L, Van Assche FA. Fetal growth and long-term consequences in animal models of growth retardation. Eur J Obstet Gynecol Reprod Biol. 1998;81:149–56.PubMedCrossRef

27.

Rhind SM, Rae MT, Brooks AN. Effects of nutrition and environmental factors on the fetal programming of the reproductive axis. Reproduction. 2001;122:205–14.PubMedCrossRef

28.

Sir-Petermann T, Maliqueo M, Angel B, et al. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod. 2002;17:2573–9.PubMedCrossRef

29.

Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest. 1998;101:2622–9.PubMedPubMedCentralCrossRef

30.

Al-Attar L, Noël K, Dutertre M, et al. Hormonal and cellular regulation of Sertoli cell anti-Müllerian hormone production in the postnatal mouse. J Clin Invest. 1997;100:1335–43.PubMedPubMedCentralCrossRef

31.

Løbo RA, Kletzky OA, Campeau JD. Elevated bioactive luteinizing hormone in women with the polycystic ovary syndrome. Fertil Steril. 1983;39:674–8.PubMedCrossRef

32.

Panidis D, Farmakiotis D, Rousso D, et al. Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur J Intern Med. 2008;19:406–12.PubMedCrossRef

33.

Panidis D, Koliakos G, Kourtis A, et al. Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril. 2004;81:361–6.PubMedCrossRef

34.

Siow Y, Kives S, Hertweck P, Perlman S, Fallat ME. Serum Müllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertil Steril. 2005;84:938–44.PubMedCrossRef

35.

Freeman EW, Gracia CR, Sammel MD, et al. Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil Steril. 2007;87:101–6.PubMedCrossRef

36.

Piouka A, Farmakiotis D, Katsikis I, et al. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab. 2009;296:E238–43.PubMedCrossRef

37.

H-x XIA, ZHANG W. Study of association between polycystic ovary syndrome and dietary intake. J Reprod Contracept. 2012;23:29–40.CrossRef

38.

Ozay AC, Emekci Ozay O, Okyay RE, et al. Different effects of Myoinositol plus folic acid versus combined Oral treatment on androgen levels in PCOS women. Int J Endocrinol. 2016;2016:3206872.PubMedPubMedCentralCrossRef

39.

Lagana AS, Rossetti P, Sapia F, et al. Evidence-based and patient-oriented inositol treatment in polycystic ovary syndrome: changing the perspective of the disease. Int J Endocrinol Metab. 2017;15:e43695.PubMedPubMedCentralCrossRef

40.

Di GC, Benzi L, Bottone P, et al. Neonatal outcome and obstetric complications in women with gestational diabetes: effects of maternal body mass index. Int J Obes Relat Metab Disord. 1996;20:445–9.

41.

Stevenson DK, Hopper AO, Cohen RS, et al. Macrosomia: causes and consequences. J Pediatr. 1982;100:515–20.PubMedCrossRef

42.

Ramsay JE, Ferrell WR, Crawford L, et al. Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J Clin Endocrinol Metab. 2002;87:4231–7.PubMedCrossRef

43.

Golden SH, Ding J, Szklo M, et al. Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women: the atherosclerosis risk in communities study. Am J Epidemiol. 2004;160:540–8.PubMedCrossRef

44.

Pellatt L, Hanna L, Brincat M, et al. Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007;92:240–5.PubMedCrossRef

45.

Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod BioMed Online. 2016;33:15–28.PubMedCrossRef

46.

Gulsen MS, Ulu I, Yildirim Kopuk S, Kiran G. The role of anti-Mullerian hormone in predicting clomiphene citrate resistance in women with polycystic ovarian syndrome. Gynecol Endocrinol. 2019;35:86–9.PubMedCrossRef

47.

Di Paola R, Garzon S. Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Arch Gynecol Obstet. 2018;298:1029–35.PubMedCrossRef

Title: Comparison of the umbilical cord Blood’s anti-Mullerian hormone level in the newborns of mothers with polycystic ovary syndrome (PCOS) and healthy mothers
Authors: Faezeh Tadaion Far
Shahideh Jahanian Sadatmahalleh
Saeideh Ziaei
Anoshirvan Kazemnejad
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Polycystic Ovary Syndrome
Polycystic Ovary Syndrome
Androgens
Published in: Journal of Ovarian Research / Issue 1/2019
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-019-0583-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of the umbilical cord Blood’s anti-Mullerian hormone level in the newborns of mothers with polycystic ovary syndrome (PCOS) and healthy mothers

Abstract

Background

Methods

Results

Conclusion(s)

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion(s)

Please log in to get access to this content

Other articles of this Issue 1/2019

Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer

Effect of transcutaneous electrical acupoint stimulation on protecting against radiotherapy- induced ovarian damage in mice

Persistently elevated alpha-fetoprotein associated with chronic hepatitis B during chemotherapy for malignant ovarian germ cell tumors: a case series and a review of the literature

Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study

CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers